Portillo's Inc. filed a Form 8-K on November 5, 2026, disclosing third-quarter financial results and a Board-approved plan to close a mid-to-high single digit number of underperforming restaurants located outside of Chicagoland.
Veracyte, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, and reporting condensed consolidated financial results for the three and nine months ended on that date.
BlackRock TCP Capital Corp. filed a Form 8-K on November 5, 2026, announcing its financial results for the third quarter ended September 30, 2026, and declaring a fourth-quarter dividend of $0.17 per share.
Gibraltar Industries, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 5, 2026, reporting sharply higher net sales driven by acquisition activity alongside significant interest expense and losses from discontinued operations.
Sempra (NYSE:SRE) reported third-quarter 2026 earnings results on November 5, 2026, disclosing GAAP earnings of $877 million and updating its full-year 2026 GAAP EPS guidance range, while announcing an expected 20% increase to Oncor's base capital plan.
Lantheus Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting third-quarter revenues of $389.9 million and nine-month net income of $215.8 million.
Acadian Asset Management Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting third-quarter and nine-month financial results.
Sonida Senior Living, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 5, 2026, reporting operations following its March 2026 merger with CNL Healthcare Properties, Inc.
Parker-Hannifin Corporation filed a Form 8-K with the SEC on November 5, 2026, reporting results of operations for the quarter ended September 30, 2026, via an attached press release.
Pyxis Oncology, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the Securities and Exchange Commission on November 5, 2026, disclosing continued net losses and a significant decline in cash and cash equivalents from the year-end 2025 …